Do Weight Loss Injections Affect Mood? What the MHRA Found

Posted on October 29, 2026 by Sally-Anne Turner

What the MHRA Investigation Really Found

You’ve seen the headlines. “Weight loss jabs linked to depression.” “Suicide risk with slimming injections.” “Mental health warning for Wegovy users.” These stories are frightening, particularly if you’re already managing anxiety or depression and considering weight loss medication. You’re left wondering: are these medications actually dangerous for your mental health? What did the regulators really find? And how do you separate genuine concerns from media sensationalism?

The truth is more nuanced and, in many ways, more reassuring than the headlines suggest. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), along with other international regulators, has investigated these concerns. Understanding what they actually found – rather than what makes for dramatic headlines – is crucial for making an informed decision about your treatment options.

This analysis examines the regulatory evidence, separates myth from reality, and provides you with the facts you need to understand the relationship between GLP-1 medications like Wegovy, Mounjaro and Saxenda and mood changes. For broader context about mental health considerations with these treatments, see our detailed guide on weight loss injections and mental health.

The Investigation: Why Regulators Examined Mental Health Concerns

In 2023, regulatory agencies began investigating potential mental health effects of certain GLP-1 receptor agonist medications. This followed reports from patients and healthcare professionals describing suicidal or self-injurious thoughts and actions. Depression was also considered during the safety reviews.

These reports came through pharmacovigilance systems – the formal channels through which suspected adverse reactions are reported and tracked. When concerning reports emerge, regulators have a responsibility to investigate. This doesn’t mean the reports prove causation; it means they warrant careful examination.

Understanding Pharmacovigilance Reporting

Here’s something crucial to understand about these reporting systems: they identify suspected adverse reactions, not necessarily proven causes.

If someone taking a medication experiences depression, it may be reported even when it’s unclear whether the medication contributed, whether the symptoms were pre-existing or whether other factors were involved.

This is by design. These systems help regulators identify possible safety signals that require further investigation. However, the raw number of reports cannot establish how frequently an adverse reaction occurs or whether a medicine caused it.

For example, if a large number of people begin taking a medication, some will experience depression during treatment simply because depression occurs in the wider population. The important question is whether the medicine increases that risk compared with what would otherwise be expected.

Researchers investigate this through clinical trials, observational studies and other evidence rather than relying on spontaneous reports alone.

The Scale of the Review

The regulatory investigations considered several types of evidence, including clinical trials, post-marketing safety reports, epidemiological studies and published scientific literature.

The European Medicines Agency (EMA) reviewed GLP-1 receptor agonists including semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide.

The MHRA examined relevant UK safety data and considered the findings of the European regulatory review.

These investigations were important because different medicines within the GLP-1 class have different indications, dosing schedules and patient populations.

It’s also important to distinguish these medicines from tirzepatide (Mounjaro), which acts on both GIP and GLP-1 receptors. The original regulatory reviews did not evaluate every currently available weight loss medicine in exactly the same way.

What the MHRA Actually Found: Evidence vs Speculation

After reviewing the available evidence, the MHRA concluded in September 2024 that the data did not support a causal association between the GLP-1 receptor agonists reviewed and suicidal behaviour, suicidal thoughts, self-injury or depression.

The MHRA’s published findings on GLP-1 medicines and mental health aligned with the European regulatory conclusions. The agency did not consider changes to the product information necessary on the basis of the evidence reviewed.

Let’s be precise about what this means.

The regulators weren’t saying these medications improve mental health. They also weren’t saying that nobody taking them could experience depression or suicidal thoughts.

Instead, the available evidence did not establish that the medicines reviewed caused these problems.

This is reassuring, but it isn’t proof that every possible psychiatric effect has been ruled out. The MHRA continues to monitor new safety information as it becomes available.

The Clinical Trial Data

Clinical trials of GLP-1 medications are particularly valuable because they can compare outcomes between people receiving medication and those receiving a placebo or another treatment.

This helps researchers investigate whether adverse events occur more frequently with the medicine than in the comparison group.

Analyses of semaglutide weight management trials have generally not identified an increased risk of suicidal thoughts or behaviours compared with placebo. However, some trials excluded people with certain severe or unstable psychiatric conditions, which limits how confidently their findings can be applied to every patient.

Evidence from tirzepatide trials has also been examined for psychiatric safety outcomes, although differences in trial populations, outcome definitions and follow-up periods make direct comparisons difficult.

It’s important not to interpret a statistically non-significant difference as proof that two treatments carry identical risks.

Controlled trials provide valuable evidence, but uncommon adverse events and outcomes in underrepresented patient groups may require continued investigation.

Real-World Evidence

Post-marketing surveillance provides a different perspective, capturing what happens when medications are used outside clinical trials by people with a wider range of health conditions and medication histories.

This real-world evidence is valuable, although it can be difficult to interpret.

For example, people seeking weight management treatment may already have depression, anxiety or other mental health conditions. Some may also be experiencing significant life stress, physical health problems or weight-related stigma.

These factors can influence mental health independently of medication.

Observational studies may use statistical methods to account for some of these differences, but they cannot always eliminate every possible source of bias.

Taken together, the available regulatory evidence has not established a causal association between the GLP-1 receptor agonists reviewed and depression, suicidal thoughts or self-harm.

However, ongoing monitoring remains appropriate, particularly as treatment becomes more widely used.

What About Individual Cases?

The fact that regulators have not established a causal association doesn’t invalidate individual experiences.

Some people report mood changes while taking weight loss medications. These symptoms deserve attention, regardless of whether the medication is ultimately identified as a contributing factor.

Several explanations may be possible. Physical side effects such as persistent nausea, vomiting or fatigue can affect wellbeing. Changes in eating patterns and body image may also create psychological challenges.

People taking certain diabetes medications alongside GLP-1 treatment may experience hypoglycaemia, which can cause symptoms such as sweating, trembling, confusion and anxiety.

Life circumstances – stress, relationship problems, work pressures and existing mental health conditions – can also influence mood.

The regulatory findings are reassuring at a population level, but they don’t establish the cause of symptoms in any individual patient.

If you experience mood changes during treatment, your healthcare provider can help investigate possible causes and determine what support or treatment changes may be appropriate.

Myth vs Evidence: Common Misconceptions Debunked

Let’s address some persistent myths about weight loss injections and mood, contrasting them with what the evidence actually shows.

Myth: These Medications Cause Depression

The evidence: Regulatory reviews have not established a causal association between the GLP-1 receptor agonists reviewed and depression.

Some clinical studies have also reported improvements in quality of life or measures of psychological wellbeing during treatment. However, these findings may be influenced by weight loss, improved physical health and other factors.

GLP-1 medications are not currently licensed in the UK to treat depression, and improvements in mood should not be assumed or guaranteed.

Depression can occur in people seeking weight loss treatment for many reasons. Obesity and depression are associated in some populations, although the relationship is complex and influenced by biological, psychological and social factors.

When someone experiences depressive symptoms after starting medication, it’s important not to assume either that the medicine caused them or that the medicine cannot be involved.

Weight loss itself can also affect wellbeing in different ways. Some people experience improvements in mobility and confidence, while others find changes in body image or eating habits challenging.

Individual assessment is more useful than drawing conclusions from headlines alone.

Myth: Suicidal Thoughts Are a Common Side Effect

The evidence: The MHRA and EMA reviews did not establish a causal association between the GLP-1 receptor agonists reviewed and suicidal or self-injurious thoughts and actions.

This does not support claims that suicidal thoughts are a common, established adverse reaction caused by these medicines.

However, suicidal thoughts can occur in people taking weight loss medications, just as they can occur in people who are not taking them.

Mental health conditions, previous experiences, life circumstances and other factors may contribute to someone’s risk.

Importantly, suicidal thoughts should never be dismissed because regulatory reviews have been reassuring.

If you experience these thoughts, seek support promptly, regardless of whether you believe your medication is involved.

Myth: You Can’t Use These Medications If You Have Mental Health Conditions

The evidence: Having a mental health condition is not automatically a contraindication to GLP-1-based weight loss treatment.

A diagnosis of depression or anxiety does not, by itself, mean someone is unsuitable for these medicines.

What matters is individual assessment, including current symptoms, medication history, nutritional status, treatment goals and any factors that may affect safety.

If you’re experiencing severe or unstable mental health symptoms, your clinician may recommend additional assessment or coordinated support before starting treatment.

However, it would be inappropriate to assume that everyone with a mental health diagnosis must delay or avoid weight loss treatment.

Many people with histories of depression or anxiety may be suitable for these medications when the potential benefits outweigh the risks.

At Bodyline, we offer specialised support for patients with mental health considerations, helping ensure treatment decisions take account of individual needs and appropriate safeguards.

Myth: The Medications Change Your Brain Chemistry Dangerously

The evidence: GLP-1 receptors are present in areas of the brain involved in appetite regulation and other physiological processes.

These medicines influence pathways involved in hunger, fullness and food intake. This is part of their intended therapeutic action.

Researchers are also investigating possible effects on reward processing, inflammation and neurological function.

However, the presence of receptors in brain regions associated with mood does not establish that these medicines cause psychiatric harm.

Equally, preliminary findings suggesting possible neurological or psychological benefits do not establish that they can treat depression or other mental health conditions.

Much of this research remains exploratory, and findings from animal studies cannot automatically be applied to patients.

The most established effects of GLP-1-based weight loss treatments concern appetite regulation, weight management and certain metabolic outcomes.

Myth: Natural Weight Loss Is Safer for Mental Health

The evidence: It’s misleading to assume that weight loss through diet and exercise has no psychological effects while medication-assisted weight loss necessarily carries mental health risks.

Any significant change in weight, eating habits or body image may affect wellbeing.

Highly restrictive diets can be difficult to sustain and may be particularly challenging for people with a history of disordered eating.

Physical activity can support mental wellbeing, but excessive or compulsive exercise can also become problematic.

Medication-assisted weight loss may make appetite management easier for some people, although it can introduce other considerations, including side effects and changes in eating patterns.

There’s no universally safer approach for every person’s mental health.

The most appropriate treatment depends on medical eligibility, individual circumstances, psychological wellbeing and the support available.

What to Actually Watch For: Realistic Monitoring

While the regulatory evidence is reassuring, monitoring your mental wellbeing during weight loss treatment remains important.

Here’s what realistic, proportionate monitoring can involve.

The First Month: Adjustment Period

The first few weeks of GLP-1-based treatment can involve gastrointestinal side effects such as nausea, vomiting, constipation or diarrhoea.

Some people also experience fatigue.

These physical symptoms can affect how you feel emotionally, particularly if you’re struggling to eat, drink or sleep adequately.

However, feeling emotionally flat, depressed or unusually anxious should not automatically be described as a normal adjustment effect.

There is no established two-to-four-week period during which new depressive symptoms can safely be ignored.

Some medication side effects improve as treatment continues, but persistent or worsening symptoms need assessment.

What to watch for: feelings of hopelessness or worthlessness, loss of interest in activities you normally enjoy, significant changes in mood or thoughts that life isn’t worth living.

These symptoms warrant prompt contact with a healthcare professional, even if you’ve only recently started treatment.

Physical Symptoms That Mimic Mood Problems

Several physical symptoms associated with weight loss treatment or other medications can overlap with symptoms of anxiety or depression.

Low blood sugar can cause shakiness, sweating, rapid heartbeat, confusion and feelings resembling panic.

The risk of hypoglycaemia is particularly relevant when certain GLP-1-based medicines are used alongside insulin or sulfonylureas. These diabetes medications may require clinician-led dose adjustments.

If you have diabetes and are at risk of hypoglycaemia, follow your individual blood glucose monitoring and treatment plan. Don’t assume that simply eating more regularly will prevent every episode.

Dehydration can develop if you’re experiencing persistent vomiting or diarrhoea. This may cause dizziness, fatigue, confusion and, in severe cases, kidney problems.

Ensuring adequate fluid intake is important, but severe or persistent symptoms require medical advice.

Nutritional deficiencies may also become a concern if your food intake remains inadequate over time.

Our Vitamin B12 Spray and Vitamin D3 Spray provide supplementation options where additional intake is appropriate.

However, these products are not treatments for depression, and supplementation is not automatically necessary for everyone taking GLP-1 medicines.

If you’re eating very little or experiencing persistent fatigue, your clinician can assess whether nutritional advice, blood tests or supplements are needed.

Psychological Adjustment Points

Certain stages of weight loss treatment can be psychologically challenging, even when treatment is progressing well medically.

The first plateau – when weight loss slows or stops temporarily – can feel frustrating. You might worry that the medication has stopped working or that your progress is slipping away.

These feelings don’t necessarily indicate depression, but persistent distress deserves attention.

Reaching significant milestones can also bring unexpected emotions. Some people feel pleased with their progress, while others find that weight loss hasn’t resolved the personal or emotional difficulties they hoped it would.

Social situations can become complicated. You might feel awkward declining food at gatherings or uncomfortable with attention to your changing appearance.

These experiences vary considerably between individuals.

Recognising them as possible challenges can help you develop coping strategies without assuming that everyone will experience the same psychological response.

Red Flags Requiring Immediate Attention

Certain symptoms require prompt or emergency mental health support.

Thoughts of self-harm or suicide should always be taken seriously, even if you’re unsure whether you would act on them.

If you’re experiencing suicidal thoughts, contact your GP, mental health team or NHS 111 for urgent support. If you’re in immediate danger or have seriously harmed yourself, call 999 or attend A&E.

The mental health charity Mind provides guidance on treatment and support for suicidal thoughts, including accessing crisis services, talking therapies and other sources of help.

Severe anxiety that interferes with daily activities, persistent panic attacks or significant changes in behaviour also deserve professional assessment.

If you become unusually withdrawn, irritable or distressed, particularly when this represents a marked change from your usual behaviour, discuss it with your healthcare provider.

A sustained loss of interest in activities, relationships or self-care, particularly alongside hopelessness, may indicate depression requiring assessment and treatment.

These symptoms are not necessarily caused by GLP-1 medication, but they should never be dismissed.

The Broader Context: Why Obesity and Mental Health Are Connected

Understanding the relationship between obesity and mental health helps explain why concerns about psychiatric symptoms can be difficult to investigate.

Biological Connections

Obesity is associated with changes in inflammation, metabolism and hormonal signalling, all of which are being studied for their possible relationships with mental health.

For example, chronic low-grade inflammation has been investigated as one potential factor linking metabolic health and depression.

Insulin resistance and other metabolic changes may also be relevant, although these relationships are complex and do not establish that obesity directly causes depression.

Hormones involved in appetite regulation, including leptin, have roles in several physiological processes. Researchers are investigating their potential involvement in mood regulation.

Sleep apnoea, which is more common in people with obesity, can disrupt sleep and is associated with poorer mental wellbeing.

Weight loss may improve some aspects of metabolic health and sleep-related symptoms. However, these improvements do not guarantee that depression or anxiety will improve.

Psychological and Social Factors

Living with obesity in a society that stigmatises it can take a psychological toll.

Weight stigma – including discrimination, prejudice and negative stereotypes – can occur in healthcare, employment, media and social situations.

Experiences of stigma may contribute to emotional distress, low self-esteem and difficulties seeking healthcare.

Many people with obesity have also experienced weight cycling, involving repeated periods of weight loss and regain.

This can be frustrating and may affect confidence in future treatment attempts.

Body image concerns can develop over many years and do not necessarily disappear with weight loss.

For some people, changes in appearance can create new psychological challenges, even when physical health improves.

Understanding that weight loss addresses some aspects of health but doesn’t automatically resolve emotional difficulties helps create more realistic expectations.

The Complexity of Correlation

This broader context helps explain why separating correlation from causation can be challenging.

When someone experiences low mood after starting weight loss medication, several explanations may be possible.

Their existing mental health condition may have changed. Physical side effects could be affecting their wellbeing. They may be experiencing psychological adjustments to weight loss, or unrelated life stressors may be contributing.

A medication-related effect may also need to be considered, even when population-level evidence has not established a causal association.

Regulatory investigations examine evidence from multiple sources to assess whether suspected adverse reactions represent genuine safety concerns.

These assessments may consider the timing of events, comparison groups, possible alternative explanations and patterns across different studies.

The available evidence has not established a causal association between the GLP-1 receptor agonists reviewed and depression, suicidal thoughts or self-harm.

However, that conclusion should not be extended to mean that these medications have no possible influence on any aspect of mental wellbeing.

Building Your Personal Safety Framework

Given the evidence, how do you approach weight loss medication safely from a mental health perspective?

Here’s a practical framework based on appropriate clinical assessment and monitoring.

Pre-Treatment Assessment

Before starting medication, an honest discussion about your relevant mental health history is important.

This may include current symptoms, past diagnoses, medications you’re taking, any history of suicidal thoughts or self-harm, and significant current stressors.

The assessment isn’t about judging you or automatically creating barriers to treatment.

It’s about understanding your individual circumstances, identifying potential concerns and planning appropriate support.

If you’re currently experiencing severe depression or anxiety, particularly with suicidal thoughts, your clinician should assess your immediate needs and whether additional mental health support is required before or alongside weight loss treatment.

This does not mean that everyone with severe mental health symptoms is automatically unsuitable for GLP-1 medicines.

Treatment decisions should reflect individual clinical circumstances rather than a blanket rule.

Coordinated Care

If you’re already working with mental health professionals – a psychiatrist, psychologist or counsellor – informing them about your weight loss treatment plans can support coordinated care.

With your consent, relevant healthcare professionals may communicate about your treatment and any concerns that arise.

If you’re taking psychiatric medications, your prescriber should review potential interactions and other factors affecting treatment suitability.

Some antidepressants and antipsychotics can influence appetite or weight.

GLP-1-based medicines can also delay gastric emptying, which may affect the absorption of certain oral medications, although the clinical significance varies.

Changes in body weight do not automatically mean psychiatric medication doses need adjusting.

Any changes should be based on the specific medicine, clinical response and advice from the responsible prescriber.

Enhanced Monitoring Protocol

For patients with significant mental health histories, additional monitoring may be appropriate, particularly during treatment initiation or dose changes.

Appointments may include questions about mood, anxiety, sleep, eating patterns and any concerning thoughts.

The level of monitoring should reflect individual needs rather than assuming that every person with a mental health diagnosis requires the same schedule.

You can also monitor your wellbeing between appointments.

Some people find a simple mood journal useful for recognising changes or identifying concerns they want to discuss with their healthcare team.

However, you shouldn’t wait a week or more before reporting serious symptoms.

New or worsening depression, significant anxiety or thoughts of self-harm require prompt attention.

Your healthcare team should explain what symptoms to watch for and how to access support between appointments.

At Bodyline, patients can discuss the support arrangements available as part of their individual treatment plan.

Psychological Support Integration

Consider whether you’d benefit from talking therapy alongside medical treatment.

Cognitive behavioural therapy (CBT) is an evidence-based treatment for several mental health conditions, including depression and anxiety, and may help some people develop coping strategies as their relationship with food changes.

Therapy can also provide support with body image, emotional eating and other psychological challenges.

It isn’t only for people with a diagnosed mental health condition.

If formal therapy isn’t accessible or appropriate, other forms of support may help.

Trusted friends or family members, peer support groups and reputable mental health resources can contribute to your support network.

However, self-help resources should not replace professional assessment when symptoms are severe or persistent.

Looking Beyond the Headlines: Making Informed Decisions

The MHRA’s findings, alongside conclusions from other regulatory agencies, provide reassurance about the concerns investigated.

The available evidence has not established a causal association between the GLP-1 receptor agonists reviewed and depression, suicidal thoughts or self-harm.

This doesn’t mean these medicines are suitable for everyone, or that mental health considerations are irrelevant.

It means decisions should be based on individual circumstances and the available evidence rather than alarming headlines alone.

Individual Risk-Benefit Assessment

Every medical treatment involves weighing potential benefits against possible risks.

For weight loss medications, benefits may include clinically meaningful weight loss, improvements in some obesity-related health conditions and better physical functioning or quality of life.

The amount of weight lost varies by medication, dose and individual response, so a single percentage should not be assumed for everyone.

Risks include common gastrointestinal side effects and less common but potentially serious complications, such as acute pancreatitis.

For people with mental health considerations, the question is whether their individual circumstances create additional needs for assessment, support or monitoring.

Someone with stable, well-managed depression may be suitable for treatment, provided they meet the relevant prescribing criteria.

Someone experiencing an acute mental health crisis needs urgent appropriate care, and the timing of elective weight management treatment may need reviewing.

These decisions require individualised assessment.

Generic advice – either “these medications are dangerous for mental health” or “they’re completely safe for everyone” – doesn’t serve patients well.

What matters is a clinical assessment that considers your complete health picture.

Questions to Ask Your Healthcare Provider

When discussing weight loss medication with mental health considerations, these questions can help ensure you get the information you need:

1. Based on my specific mental health history, do you see any particular concerns with these medications for me?
2. What monitoring will be in place to detect any mood changes early?
3. How often will we review my mental wellbeing, and what should I watch for between appointments?
4. What should I do if I notice mood changes or concerning thoughts?
5. Should my mental health provider be involved in this treatment plan?
6. Are there any interactions between these medications and my psychiatric medications?
7. What support is available if I struggle psychologically with the changes?

Healthcare providers should answer these questions clearly and explain how concerns will be managed.

Rather than relying on vague reassurance, you should understand what monitoring and support will be available during treatment.

Realistic Expectations

Understanding what weight loss can and can’t change helps prevent disappointment and supports better mental health outcomes.

Weight loss may improve physical health markers, mobility, some obesity-related symptoms and quality of life.

Some people also experience improvements in confidence or body satisfaction, although this isn’t universal.

What weight loss doesn’t automatically fix includes underlying mental health conditions, relationship problems, work stress, financial concerns or longstanding body image difficulties.

If you’re hoping weight loss will solve all life’s problems, you may be disappointed.

This doesn’t mean weight loss isn’t worthwhile – it means keeping realistic expectations about its benefits.

Some people find that weight loss brings unexpected challenges.

Relationships may change, attention to your appearance may feel uncomfortable, or you may need new ways to manage emotions if food has previously been a source of comfort.

These adjustments vary between individuals and may benefit from additional support.

Moving Forward with Evidence-Based Confidence

The MHRA investigation into GLP-1 medications and mental health demonstrates why suspected adverse reactions need careful scientific assessment.

Concerns were raised, the available evidence was reviewed, and regulators concluded that it did not support a causal association between the GLP-1 receptor agonists reviewed and depression, suicidal thoughts or self-harm.

This provides important reassurance.

However, it doesn’t mean individual experiences should be dismissed or that ongoing monitoring is unnecessary.

For many people, including those with mental health histories, GLP-1-based weight loss treatment may be appropriate following an individual clinical assessment.

Your mental health considerations don’t automatically disqualify you from treatment.

They help inform how treatment should be assessed, what monitoring may be needed and what support should be available.

Weight loss medication is one tool among many for improving health and wellbeing.

When used appropriately, with realistic expectations and clinical support, it may offer meaningful benefits.

The key is approaching treatment with accurate information rather than fear, while recognising both its potential benefits and limitations.

If you’re considering weight loss medication and have concerns about mental health impacts, the most important step is having an honest conversation with qualified healthcare professionals.

They can assess your individual situation, discuss the potential risks and benefits, and help you make an informed decision about whether treatment is appropriate.

Book a no-obligation consultation today to discover how we can help you work towards your health goals while prioritising your mental wellbeing.

Our team at Bodyline provides personalised care that considers your complete health picture, helping ensure treatment recommendations reflect your individual needs.

We offer specialised support for patients with mental health considerations, with assessment and monitoring tailored to clinical suitability and patient needs.

The available evidence is reassuring, but appropriate assessment and monitoring remain important.

Rather than allowing sensationalised headlines to determine your decision, seek reliable information and professional guidance so you can choose the approach that’s right for you.